Evidence map›Paper›PMID 34795156›Full record

ArticleThe Kobe journal of medical sciences2021

Serum Cytokine Profiles of Rapid Recovery Patients with COVID-19: Series of 6 Cases.

Goh Ohji, Yohei Funakoshi, Kei Ebisawa, Kimikazu Yakushijin, Yu Arakawa, Jun Saegusa, Shinichiro Kawamoto, Takamitsu Imanishi, Yasuko Mori, Kentaro Iwata and 1 more

Abstract readCase Reports
PubMed Full text at PMC
In one paragraph

Article in The Kobe journal of medical sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Goh OhjiDivision of Infectious Disease Therapeutics, Department of Microbiology and Infectious Diseases, Kobe University Graduate School of Medicine, Kobe, Japan.
Yohei FunakoshiDivision of Medical Oncology/Hematology, Department of Medicine, Kobe University Hospital and Graduate School of Medicine, Kobe, Japan.
Kei EbisawaDivision of Infectious Disease Therapeutics, Department of Microbiology and Infectious Diseases, Kobe University Graduate School of Medicine, Kobe, Japan.
Kimikazu YakushijinDivision of Medical Oncology/Hematology, Department of Medicine, Kobe University Hospital and Graduate School of Medicine, Kobe, Japan.
Yu ArakawaDivision of Infectious Disease Therapeutics, Department of Microbiology and Infectious Diseases, Kobe University Graduate School of Medicine, Kobe, Japan.
Jun SaegusaDepartment of Clinical Laboratory, Kobe University Hospital, Kobe, Japan.
Shinichiro KawamotoDepartment of Transfusion Medicine and Cell Therapy, Kobe University Hospital, Kobe, Japan.
Takamitsu ImanishiDepartment of Clinical Laboratory, Kobe University Hospital, Kobe, Japan.
Yasuko MoriDivision of Clinical Virology, Center for Infectious Diseases, Kobe University Graduate School of Medicine, Kobe, Japan.
Kentaro IwataDivision of Infectious Disease Therapeutics, Department of Microbiology and Infectious Diseases, Kobe University Graduate School of Medicine, Kobe, Japan.
Hironobu MinamiDivision of Medical Oncology/Hematology, Department of Medicine, Kobe University Hospital and Graduate School of Medicine, Kobe, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

COVID-19 patients reveal various clinical manifestations; however, the specific mechanisms and factors contributing to rapid recovery remain unclear. We performed serum cytokine profiling using a bead-based immunoassay in six COVID-19 patients with mild symptoms who experienced rapid recovery. All patients had fever that resolved within 4 days. During the study, the interferon gamma-related protein 10 (IP-10) level rapidly increased initially, and then rapidly decreased in all six patients. Similarly, the interferon (IFN)-λ 2/3 levels rapidly increased initially, and then decreased in five of the six patients. IP-10 and IFN-λ2/3 may play a key role in the rapid recovery of mild COVID-19.

Indexed as

Immunity, InnateAdultBiomarkersCOVID-19COVID-19 TestingCytokinesDisease ProgressionFemaleHumansMaleMiddle AgedPrognosisSeverity of Illness IndexBiomarkersCytokinesCOVID-19IFN-λ2/3IP-10SARS-CoV-2

Identifiers

PMID34795156
PMCPMC8622216

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.